Why the Number of Brain Metastases Shapes Every Treatment Decision
When cancer spreads to the brain, your doctors will ask two key questions: where is it, and how many lesions are there? The number matters because it shapes your treatment plan. Doctors call this tumor burden. It means the total number of metastatic lesions in your brain, how big they are, and whether new ones are forming. Tumor burden is one of the biggest factors in deciding if you can have surgery, which kind of radiation makes sense, and whether treatment aims to get rid of the cancer or ease symptoms.
This article explains how your treatment plan changes based on the number of lesions. Understanding this can help you ask better questions when you meet with a neurosurgeon or radiation oncologist.
What "Tumor Burden" Actually Means
Doctors look at three things when they measure tumor burden in brain metastases:
- Number of lesions — seen on an MRI scan with contrast. Even tiny lesions show up clearly.
- How big each lesion is — a 4-centimeter lesion pressing on important brain areas gets treated very differently from a 5-millimeter spot.
- How fast they're growing — are new lesions appearing every 6 to 8 weeks, or has your brain been stable for months?
These factors work together. A patient with two large, fast-growing lesions may have worse symptoms than a patient with four tiny, stable ones. Your team looks at all three before planning treatment.
The Single Metastasis: When Surgery Enters the Conversation
One brain lesion with controlled cancer elsewhere in your body is the most likely scenario for surgery. A Cochrane systematic review of surgery versus radiosurgery for single brain metastases found that both approaches work well for the right patients, depending on lesion size, location, and individual factors.
Doctors usually consider surgery when all of these are true:
- The lesion is in an easy-to-reach location. Deep tumors in the brainstem, thalamus, or basal ganglia usually carry too much risk.
- The lesion is large, often bigger than 3 centimeters, or is causing serious swelling, shifting, or blocked fluid flow that affects your brain function.
- You have good performance status. Doctors use the Karnofsky Performance Scale (KPS) to measure this. A score of 70 or higher means you can manage daily life on your own. This is usually needed for surgery.
- Your main cancer is controlled or stable. If your primary tumor is growing fast elsewhere, removing one brain lesion may not help much.
- Removing the tumor would give tissue for genetic testing. This matters if the primary site is unknown or if genetic data could lead to targeted therapy.
When these conditions are met, surgery can relieve symptoms fast, reduce the need for steroids, and give doctors tissue to study. The goal is to remove as much tumor as safely possible without causing new brain damage.
Radiation After Surgery for a Single Metastasis
Surgery alone is almost never the end of treatment. The surgical site and any leftover cancer cells need radiation. For many years, whole-brain radiation therapy (WBRT) was standard after surgery. Most major cancer centers have changed this.
Major cancer centers like Memorial Sloan Kettering Cancer Center and Dana-Farber Cancer Institute now usually prefer stereotactic radiosurgery (SRS) to the surgical cavity instead of whole-brain radiation. SRS sends a high dose of radiation to a small, exact target. It spares the hippocampus and the healthy brain around it.
Doctors have moved away from WBRT after surgery because research showed it raised the risk of memory problems without improving survival for patients with fewer lesions. Modern oncology prefers to treat the specific target and protect everything else.
When the Single-Lesion Patient Cannot Have Surgery
Not all patients with one brain metastasis can have surgery. If the lesion is in a deep or critical area, or if other health issues make surgery too risky, SRS alone may be the primary treatment. SRS for a single metastasis is a proven approach with strong evidence for controlling the tumor when lesions are an appropriate size.
The main trade-off: SRS does not give tissue for biopsy. If knowing the exact type of cancer or genetic makeup would change your systemic treatment, surgery might still be better even for smaller, reachable lesions.
Oligometastatic Disease: 2 to 4 Lesions
Oligometastatic is a term doctors use for a small number of metastatic lesions, typically four or fewer. This group is different from both larger groups. These patients usually can't have surgery, but don't need whole-brain radiation either.
For patients with two to four brain metastases, doctors at major cancer centers now usually treat each lesion with SRS if each one is small enough. A systematic review and meta-analysis examining SRS versus WBRT across multiple studies of intracranial metastases found that SRS preserved thinking and memory skills better than WBRT, with similar survival rates. This evidence has led doctors to use more SRS in this group.
Surgery may still be an option if one lesion is large, causing symptoms, or pressing on the brain while the smaller ones can be treated with SRS afterward. This requires careful case-by-case review, usually with a team of neurosurgeons, radiation oncologists, and medical oncologists discussing the patient together.
What Changes When You Have 5 or More Lesions
Historically, five or more brain lesions meant doctors used WBRT. The reason was that treating many lesions with individual SRS was hard to do, took a long time, and raised concerns about total radiation exposure to the healthy brain.
This thinking is changing. Recent research shows that SRS can work for patients with 5 to 10 or even more small metastases. The main reason is quality of life. Studies on how brain radiation affects thinking consistently show that WBRT causes real drops in memory, attention, and thinking speed. These can start within months and may last. SRS spares the hippocampus and healthy brain tissue, so it carries much less risk to thinking.
When doctors do use WBRT for patients with more lesions, major cancer centers now try two things to protect thinking:
- Hippocampal avoidance (HA-WBRT): Doctors shape the radiation to avoid the hippocampus, the part of the brain that handles memory. This needs special planning software and advanced radiation tools. Studies suggest it may help prevent memory loss compared to standard WBRT. Not all centers offer it. Ask your doctor if it's available.
- Memantine: Doctors may give you this drug alongside WBRT. Research shows it may help keep your memory working better. Not all centers use it. Talk to your radiation doctor about it.
Doctors rarely use surgery as the main treatment for five or more metastases. Removing multiple tumors requires multiple surgeries and makes surgery riskier. They might use it if one big lesion is pressing on the brain and you need emergency help, with radiation treating the smaller ones.
Performance Status: The Constant Filter
No matter how many lesions you have, your performance status affects every treatment choice. Patients who can take care of themselves and stay active usually do well with surgery or SRS. Patients who spend a lot of time in bed due to brain or other health problems may struggle with these treatments. For them, gentler treatment might be better.
Your team may use a scoring tool called the Graded Prognostic Assessment (GPA). It takes into account your age, how well you function, the number of brain metastases, and whether cancer has spread elsewhere. The GPA helps doctors have honest talks about treatment goals. It's a tool to help you and your doctors decide together, not a limit on what can be tried.
The Role of the Primary Tumor Type
Not all brain metastases behave the same way. Your main cancer's biology affects which local treatments work best and how they mix with systemic therapy. Some cancers, including certain lung cancers with EGFR or ALK changes, HER2-positive breast cancers, and some melanomas, have drugs that can cross into the brain. When this is the case, timing between systemic therapy and radiation gets tricky. Some drugs may help radiation work better; others may need to be stopped around the time of SRS. You need a team of doctors working together to plan treatment.
Genetic testing of surgically removed brain tumor tissue can sometimes find targetable changes not found in the original tumor. The brain lesion might be genetically different from the original cancer site. To learn more about how genetic testing shapes treatment planning, see our article on what molecular tests your tumor actually needs and why your genetic profile determines your treatment plan.
Pre-Operative SRS: An Emerging Sequence
One newer approach to know about is pre-operative SRS. Instead of radiating the empty cavity after surgery, doctors treat the intact tumor with radiation before surgery. The theory is that radiation works better on a healthy, well-oxygenated tumor, and it might stop cancer from spreading during surgery.
Clinical trials are actively testing this approach. Most centers don't use pre-operative SRS yet, but it shows how doctors are changing the order of surgery and radiation, especially for larger, removable single metastases at major cancer centers. Ask if your hospital is studying or using this approach.
Leptomeningeal Disease: When the Picture Changes Completely
One critical difference that changes all treatment plans is whether your metastases are parenchymal (separate lesions within brain tissue itself) or whether you have leptomeningeal disease (LMD). In LMD, cancer spreads along the brain surface, the spinal cord, or in the fluid around the brain. LMD shows up as a coating on contrast MRI and may need fluid analysis to confirm.
Local radiation, including SRS to individual lesions, doesn't work well when cancer has spread this way. LMD changes the entire treatment plan. Spotting the difference between the two is one of the most important things your radiologist and neuro-oncologist will do at diagnosis and at every follow-up scan.
Radiation Necrosis Risk After SRS
One complication of SRS, more important when treating many lesions or retreating old radiation areas, is radiation necrosis. This is damage to normal brain tissue at or near the treated site. It can show up on MRI weeks to months after SRS and may look like tumor growth or return. The risk is higher when SRS is given to an area that was radiated before, when lesions are large, and as you get more SRS treatments to the brain over time. Understanding this risk is part of informed consent and your follow-up plan for anyone getting SRS. For more on how doctors tell radiation injury from tumor return on imaging, see our article on radiation necrosis versus tumor recurrence and what your options are.
A Note for Caregivers
Treatment planning for brain metastases happens fast and often within days of diagnosis. Caregivers going through this with a loved one need to understand how treatment changes based on lesion count. What does it mean when a doctor says surgery is off the table? Why do radiation plans change between appointments? For a broader guide to supporting someone through brain metastasis care, see our article on caregiving for a patient with brain metastases: what family members and friends need to know.
When to Talk to Your Doctor
Bring up tumor burden directly with your care team if:
- You don't know the exact number of lesions on your most recent MRI or whether new ones have appeared since your last scan.
- You were told surgery is not an option and want to understand why. Is it the location, the size, your performance status, or the total number of lesions?
- You're wondering if SRS is available to you and whether your lesion count disqualifies you. Even if you have five or more lesions, ask about SRS.
- WBRT has been recommended and you want to know if hippocampal-avoidance WBRT or memantine are options at your center.
- You're thinking about a second opinion from a dedicated brain metastasis program at a major cancer center.
This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.